MarcCantillonMD

Psychiatry • Livingston, NJ

Addiction, Forensic Psychiatry, Neuropsychiatry

Psychiatrists in Livingston

Join to view full profile

Dr. Cantillon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Cantillon's full profile

Already have an account?

Office
134 Walnut St
Livingston, NJ 07039
Phone+1 973-462-0496
Is this information wrong?

Summary

1. Person-centered evidence-based diagnosis and treatments (psychotherapy, pharmaceutical and complementary medicines, exercise, family and legal support
2. Clinical research neuropsychiatric disorders

Education & Training

National Institutes of Health Clinical CenterResidency, Psychiatry, 1992 - 1995
Icahn School of Medicine at Mount Sinai (Beth Israel)Residency, Psychiatry, 1990 - 1992
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 1989 - 1989
Karolinska Institute Faculty of MedicineClass of 1987

Certifications & Licensure

NJ State Medical License 2004 - 2025
NY State Medical License 1994 - 2021
PA State Medical License 2009 - 2020
MD State Medical License Active through 2020
DE State Medical License 2002 - 2020
American Board of Psychiatry and Neurology Psychiatry
American Board of Psychiatry and Neurology Brain Injury Medicine

Awards, Honors, & Recognition

McLean Award American College of Psychiatrists, 2002
CMS Meaningful Use Stage 1 Certification Practice Fusion EHR, Practice Fusion, Inc., 2011-2013

Clinical Trials

The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep Start of enrollment: 2008 Oct 01
Completed
Phase 1
Pilot Study of Duloxetine in Adult Attention Deficit Hyperactivity Disorder(ADHD) Start of enrollment: 2009 Aug 01
Completed
Phase 2
Evaluation of Oral Needs of Children With Disorder Attention Deficit/Hyperactivity Disorder Start of enrollment: 2009 May 01
Unknown status
Teen Marijuana Check-Up Start of enrollment: 2011 Mar 01
Completed
Phase 3
Vilazodone Treatment for Marijuana Dependence Start of enrollment: 2012 Aug 01
Completed
Phase 2
Nocturnal Parkinson's Disease Symptoms Study Group Start of enrollment: 2012 Nov 01
Completed
What Elements of the Design of a Healing Garden Are Used as Landmarks by Patients With Alzheimer's Disease to Locate? Start of enrollment: 2012 Aug 01
Completed
Not Applicable
A Post Marketing Observational Study of Activities of Daily Living in Advanced Parkinson's Disease Patients With Early Troublesome Motor Fluctuations and Treated With Duodopa - a Multi-country Study Start of enrollment: 2013 Feb 01
Completed
Fixed or Self-Titrated Dosages of Sativex on Cannabis Users Start of enrollment: 2013 Feb 01
Completed
Not Applicable
The Effects of Exercise in Parkinson's Disease Start of enrollment: 2013 Apr 01
Completed
Not Applicable
A Phase 2 Study to Evaluate the Safety and Efficacy of RM-131 in Patients With Parkinson's Disease & Chronic Constipation Start of enrollment: 2013 Sep 01
Terminated
Phase 2
Identifying Characteristic Signature of Attention Deficit / Hyperactivity Disorder (ADHD) and Ritalin Treatment Start of enrollment: 2013 Oct 01
Unknown status
Not Applicable
Biomarker Discovery in Parkinson's Disease Start of enrollment: 2013 Dec 01
Unknown status
Alzheimer's Prevention Registry: A Program to Accelerate Enrollment Into Studies Start of enrollment: 2012 May 01
Recruiting
A Randomized Controlled Study of Cognitive Behavioral Therapy for Adults With Attention Deficit Disorder Start of enrollment: 2013 Oct 01
Completed
Not Applicable
Efficacy of Isradipine in Early Parkinson Disease Start of enrollment: 2014 Nov 01
Completed
Phase 3
Study for the Early Diagnosis of Parkinson's Disease Start of enrollment: 2014 Nov 01
Unknown status
Neuroscience of Marijuana Impaired Driving Start of enrollment: 2016 Oct 01
Completed
Phase 1
Effectiveness of a Personalized Neurofeedback Training Device (ADHD@Home) in Attention-Deficit/Hyperactivity Disorder Start of enrollment: 2016 Aug 01
Unknown status
Phase 1, Phase 2
Deep Brain Stimulation (DBS) for Parkinson's Disease International Study Start of enrollment: 2017 Jul 26
Completed
Phenomenological and Psychopathological Factors Associated to Hallucinations in Parkinson's Disease Start of enrollment: 2017 May 15
Terminated
Development and Evaluation of a Guide to Help People With Parkinson's and Their Caregivers to Self-manage Falling Start of enrollment: 2017 May 01
Unknown status
Not Applicable
Examine the Feasibility of a Standardized Field Test for Marijuana Impairment: Laboratory Evaluations Start of enrollment: 2017 Dec 01
Completed
Early Phase 1
Effect of Medical Marijuana on Neurocognition and Escalation of Use Start of enrollment: 2017 Jul 01
Completed
Not Applicable
Perception, Cognition, and Gait in Parkinson's Disease Start of enrollment: 2017 Apr 01
Completed
Safety and Efficacy of Cannabis in Tourette Syndrome Start of enrollment: 2018 Jan 15
Terminated
Phase 2
Effects of Marijuana on Symptoms of OCD Start of enrollment: 2017 Oct 01
Completed
Phase 1, Phase 2
A Phase 3 Study With P2B001 in Subjects With Early Parkinson's Start of enrollment: 2018 Jan 19
Completed
Phase 3
Predictors of Gait Improvement in Patients With Parkinson's Disease After Rehabilitation Start of enrollment: 2014 May 01
Completed
Blood Biomarker of Alzheimer's Disease (AD) Start of enrollment: 2018 Mar 12
Completed
Blood Biomarker in Early Parkinson's Disease Start of enrollment: 2018 Jan 22
Completed
Reported Time Between Onset and Diagnosis of Alzheimer's Disease: Correlation With Objective Parameters Start of enrollment: 2016 May 01
Completed
Exploration of the Enteric Nervous System in Alzheimer Disease Start of enrollment: 2018 Apr 26
Withdrawn
Not Applicable
The Reliability, Validity, and Responsiveness of the Timed 360° Turn Test in Patients With Parkinson's Disease Start of enrollment: 2018 Jul 20
Completed
Cannabis Use and Epigenetic Alterations in Human Male Sperm Cells Start of enrollment: 2017 Nov 07
Completed
Parkinson's Disease Inflammatory Biomarker Profiling Start of enrollment: 2018 Jul 10
Recruiting
Early Onset Alzheimer's Disease Genomic Study Start of enrollment: 2017 Jun 16
Recruiting
The Chinese Familial Alzheimer's Network Start of enrollment: 2005 Jan 10
Recruiting
Join now to see all

Publications & Presentations

PubMed

25 citations
Apathy as a Treatment Target in Alzheimer's Disease: Implications for Clinical Trials.
Moyra E. Mortby, Lawrence Adler, Luis Agüera-Ortiz, Daniel R. Bateman, Henry Brodaty, Marc Cantillon, Yonas E. Geda, Zahinoor Ismail, Krista L. Lanctôt, Gad A. Marshal...> ;The American Journal of Geriatric Psychiatry. 2021 Jul 1
706 citations
Whitepaper: Defining and investigating cognitive reserve, brain reserve, and brain maintenance
Yaakov Stern, Eider M. Arenaza-Urquijo, David Bartrés-Faz, Sylvie Belleville, Marc Cantilon, Gaël Chételat, Michael Ewers, Nicolai Franzmeier, Gerd Kempermann, William...> ;Alzheimer's & Dementia. 2020 Sep 1
8 citations
An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson's Disease and Depression.
Daryl DeKarske, Gustavo Alva, Jason L. Aldred, Bruce Coate, Marc Cantillon, Lori Jacobi, Rene Nunez, James C. Norton, Victor Abler> ;Journal of Parkinson's Disease. 2020 Jan 1
30 citations
Mechanisms underlying resilience in ageing
Yaakov Stern, Gaël Chételat, Christian G. Habeck, Eider M. Arenaza-Urquijo, Prashanthi Vemuri, Ainara Estanga, David Bartrés-Faz, Marc Cantillon, Sean A. P. Clouston, ...> ;Nature Reviews. Neuroscience. 2019 Apr 1
4 citations
Affective and emotional dysregulation as pre-dementia risk markers: exploring the mild behavioral impairment symptoms of depression, anxiety, irritability, and euphori...
Zahinoor Ismail, Jennifer Gatchel, Daniel R Bateman, Ricardo Barcelos-Ferreira, Marc Cantillon, Judith Jaeger, Nancy J Donovan, Moyra E Mortby> ;International Psychogeriatrics. 2019 Jan 1
5 citations
Initial Clinical Experience of RP5063 Following Single Doses in Normal Healthy Volunteers and Multiple Doses in Patients with Stable Schizophrenia.
Marc Cantillon, Robert Ings, Laxminarayan Bhat> ;Clinical and Translational Science. 2018 Jul 1
5 citations
Pharmacokinetics of RP5063 Following Single Doses to Normal Healthy Volunteers and Multiple Doses Over 10 Days to Stable Schizophrenic Patients.
Marc Cantillon, Robert Ings, Laxminarayan Bhat> ;Clinical and Translational Science. 2018 Jul 1
4 citations
Evaluation of the effects of RP5063, a novel, multimodal, serotonin receptor modulator, as single-agent therapy and co-administrated with sildenafil, bosentan, and tre...
Laxminarayan Bhat, Jon E. Hawkinson, Marc Cantillon, Dasharatha G. Reddy, Seema Rani Bhat, Charles-E. Laurent, Annie Bouchard, Marzena Biernat, Dany Salvail> ;European Journal of Pharmacology. 2018 May 15
3 citations
A Population Pharmacokinetic and Pharmacodynamic Analysis of RP5063 Phase 2 Study Data in Patients with Schizophrenia or Schizoaffective Disorder.
Marc Cantillon, Robert Ings, Arul Prakash, Laxminarayan Bhat> ;European Journal of Drug Metabolism and Pharmacokinetics. 2018 Apr 4
54 citations
Affective and emotional dysregulation as pre-dementia risk markers: exploring the mild behavioral impairment symptoms of depression, anxiety, irritability, and euphoria.
Zahinoor Ismail, Jennifer Gatchel, Daniel R Bateman, Ricardo Barcelos-Ferreira, Marc Cantillon, Judith Jaeger, Nancy J Donovan, Moyra E Mortby> ;International Psychogeriatrics. 2018 Feb 1
2 citations
Response to concerns over Cantillon et al. dopamine serotonin stabilizer RP5063 clinical trial's design, analyses and findings (SCHRES-D-17-00455) by Ahmed S Aboraya, ...
Marc Cantillon, Laxminarayan Bhat> ;Schizophrenia Research. 2018 Feb 1
9 citations
Effects of Rifampin on the Pharmacokinetics of a Single Dose of Istradefylline in Healthy Subjects
Mayumi Mukai, Tatsuo Uchimura, Xiaoping Zhang, Douglas Greene, Maria Vergeire, Marc Cantillon> ;Journal of Clinical Pharmacology. 2018 Feb 1
15 citations
RP5063, a novel, multimodal, serotonin receptor modulator, prevents monocrotaline-induced pulmonary arterial hypertension in rats.
Laxminarayan Bhat, Jon E. Hawkinson, Marc Cantillon, Dasharatha G. Reddy, Seema Rani Bhat, Charles E. Laurent, Annie Bouchard, Marzena Biernat, Dany Salvail> ;European Journal of Pharmacology. 2017 Sep 5
10 citations
RP5063, a novel, multimodal, serotonin receptor modulator, prevents Sugen 5416-hypoxia-induced pulmonary arterial hypertension in rats.
Laxminarayan Bhat, Jon E. Hawkinson, Marc Cantillon, Dasharatha G. Reddy, Seema Rani Bhat, Charles E. Laurent, Annie Bouchard, Marzena Biernat, Dany Salvail> ;European Journal of Pharmacology. 2017 Sep 5
25 citations
Dopamine serotonin stabilizer RP5063: A randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schiz...
Marc Cantillon, Arul Prakash, Ajay Alexander, Robert Ings, Dennis Sweitzer, Laxminarayan Bhat> ;Schizophrenia Research. 2017 Feb 16
67 citations
Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alz...
Derek L. G. Hill, Adam J. Schwarz, Maria Isaac, Luca Pani, Spiros Vamvakas, Robert Hemmings, Maria C. Carrillo, Peng Yu, Jia Sun, Laurel A. Beckett, Marina Boccardi, J...> ;Alzheimer's & Dementia. 2014 Jul 1
Understanding placebo responses in Alzheimer's disease clinical trials from the literature meta-data and CAMD database.
Ito K Corrigan B Romero K Anziano R Neville J Stephenson D Lalonde R> ;J Alzheimers Dis. 2013
33 citations
Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease
Stewart A. Factor, Kenneth Wolski, Daniel M. Togasaki, Susan Huyck, Marc Cantillon, Tony W. Ho, Robert A. Hauser, Emmanuelle Pourcher> ;Movement Disorders. 2013 Jun 1
42 citations
The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier)
Adam L. Boxer, Michael Gold, Edward D. Huey, William T. Hu, Howard J. Rosen, Joel H. Kramer, Fen-Biao Gao, Edward A. Burton, Tiffany W. Chow, Aimee W. Kao, Blair R. Le...> ;Alzheimer's & Dementia. 2013 Mar 1
Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development.
Boxer AL, Gold M, Huey E, Gao F, Burton EA, Chow T, Kao A, Leavitt BR, Lamb B, Grether M, Knopman D, Cairns NJ, Mackenzie IR, Mitic L, Roberson ED, Van Kammen D, Canti...> ;Alzheimers Dement. 2013-03-01
155 citations
Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease
Clifford R. Jack, Frederik Barkhof, Matt A. Bernstein, Marc Cantillon, Patricia E. Cole, Charles DeCarli, Bruno Dubois, Simon Duchesne, Nick C. Fox, Giovanni B. Frison...> ;Alzheimer's & Dementia. 2011 Jul 1
41 citations
Rolapitant for the prevention of postoperative nausea and vomiting: a prospective, double-blinded, placebo-controlled randomized trial.
Tong J. Gan, Jiezhun Gu, Neil Singla, Frances Chung, Michael H. Pearman, Sergio D. Bergese, Ashraf S. Habib, Keith A. Candiotti, Yi Mo, Susan Huyck, Mary R. Creed, Mar...> ;Anesthesia and Analgesia. 2011 Apr 1
140 citations
Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial
Robert A. Hauser, Marc Cantillon, Emmanuelle Pourcher, Federico Micheli, Vincent Mok, Marco Onofrj, Susan Huyck, Kenneth Wolski> ;The Lancet. Neurology. 2011 Mar 1
39 citations
Evaluation of the exposure equivalence of oral versus intravenous temozolomide.
Blanca D. Diez, Paul Statkevich, Yali Zhu, Malaz Abutarif, Fengjuan Xuan, Bhavna Kantesaria, David L. Cutler, Marc Cantillon, Max Schwarz, María Guadalupe Pallotta, Fa...> ;Cancer Chemotherapy and Pharmacology. 2010 Mar 1
The Coalition Against Major Diseases: developing tools for an integrated drug development process for Alzheimer's and Parkinson's diseases.
Romero K de Mars M Frank D Anthony M Neville J Kirby L Smith K Woosley RL> ;Clin Pharmacol Ther. 2009 Oct
Join now to see all

Journal Articles

The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier)
Boxer AL, Gold M, Huey E, Hu WT, Rosen H, Kramer J, Gao FB, Burton EA, Chow T, Kao A, Leavitt BR, Lamb B, Grether M, Knopman D, Cairns NJ, Mackenzie IR, Mitic L, Rober..., Alzh Dementia, 1/1/2013

Press Mentions

Possible PAH Treatment, Now in Testing as Anti-Psychotic, Named Orphan Drug by FDANovember 21st, 2016
Reviva Pharmaceuticals Receives FDA Orphan Designation for Pulmonary Arterial Hypertension (PAH)November 17th, 2016
FDA Grants Orphan Drug Status to Novel PAH TreatmentNovember 17th, 2016
Join now to see all